Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.

Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.

Front Physiol. 2012;3:460

Authors: Brannan JD, Lougheed MD

Abstract
Airway hyperresponsiveness (AHR) and airway inflammation are key pathophysiological features of asthma. Bronchial provocation tests (BPTs) are objective tests for AHR that are clinically useful to aid in the diagnosis of asthma in both adults and children. BPTs can be either “direct” or “indirect,” referring to the mechanism by which a stimulus mediates bronchoconstriction. Direct BPTs refer to the administration of pharmacological agonist (e.g., methacholine or histamine) that act on specific receptors on the airway smooth muscle. Airway inflammation and/or airway remodeling may be key determinants of the response to direct stimuli. Indirect BPTs are those in which the stimulus causes the release of mediators of bronchoconstriction from inflammatory cells (e.g., exercise, allergen, mannitol). Airway sensitivity to indirect stimuli is dependent upon the presence of inflammation (e.g., mast cells, eosinophils), which responds to treatment with inhaled corticosteroids (ICS). Thus, there is a stronger relationship between indices of steroid-sensitive inflammation (e.g., sputum eosinophils, fraction of exhaled nitric oxide) and airway sensitivity to indirect compared to direct stimuli. Regular treatment with ICS does not result in the complete inhibition of responsiveness to direct stimuli. AHR to indirect stimuli identifies individuals that are highly likely to have a clinical improvement with ICS therapy in association with an inhibition of airway sensitivity following weeks to months of treatment with ICS. To comprehend the clinical utility of direct or indirect stimuli in either diagnosis of asthma or monitoring of therapeutic intervention requires an understanding of the underlying pathophysiology of AHR and mechanisms of action of both stimuli.

PMID: 23233839 [PubMed – in process]

View full post on pubmed: asthma

Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen’s … – Laser Focus world

Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen's
Laser Focus world
Maxwell Biotech Venture Fund (MBVF), founded with the help of Russian government-backed RVC, announced today that its investment committee approved the terms and the amount of an investment in Eleventa, a Russian biotech company, which was

View full post on asthma – Google News

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for … – Sacramento Bee

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for
Sacramento Bee
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product
Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid News-Medical.net
Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech StreetInsider.com (subscription)

all 4 news articles »

View full post on asthma – Google News

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for … – The Herald | HeraldOnline.com

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for
The Herald | HeraldOnline.com
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product
Rigel Pharma (RIGL) Starts Clinical Studies For Asthma, Discoid LupusiStockAnalyst
Rigel Begins Trial With Advanced Proprietary Therapeutic Product CandidatesNASDAQ

all 13 news articles »

View full post on asthma – Google News

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at … – News-Medical.net

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at
News-Medical.net
Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be

and more »

View full post on asthma – Google News

New data from Boehringer Ingelheim and Pfizer’s tiotropium clinical studies on … – News-Medical.net

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on
News-Medical.net
New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for
BOEHRINGER INGELHEIM GMBH : Key results from new tiotropium studies in 4-traders

all 6 news articles »

View full post on asthma – Google News

Using a knowledge translation framework to implement asthma clinical practice guidelines in primary care.

Using a knowledge translation framework to implement asthma clinical practice guidelines in primary care.

Int J Qual Health Care. 2012 Aug 14;

Authors: Licskai C, Sands T, Ong M, Paolatto L, Nicoletti I

Abstract
Quality problemInternational guidelines establish evidence-based standards for asthma care; however, recommendations are often not implemented and many patients do not meet control targets.Initial assessmentRegional pilot data demonstrated a knowledge-to-practice gap.Choice of solutionsWe engineered health system change in a multi-step approach described by the Canadian Institutes of Health Research knowledge translation framework.ImplementationKnowledge translation occurred at multiple levels: patient, practice and local health system. A regional administrative infrastructure and inter-disciplinary care teams were developed. The key project deliverable was a guideline-based interdisciplinary asthma management program. Six community organizations, 33 primary care physicians and 519 patients participated. The program operating cost was $290/patient.EvaluationSix guideline-based care elements were implemented, including spirometry measurement, asthma controller therapy, a written self-management action plan and general asthma education, including the inhaler device technique, role of medications and environmental control strategies in 93, 95, 86, 100, 97 and 87% of patients, respectively. Of the total patients 66% were adults, 61% were female, the mean age was 35.7 (SD = ±24.2) years. At baseline 42% had two or more symptoms beyond acceptable limits vs. 17% (P< 0.001) post-intervention; 71% reported urgent/emergent healthcare visits at baseline (2.94 visits/year) vs. 45% (1.45 visits/year) (P< 0.001); 39% reported absenteeism (5.0 days/year) vs. 19% (3.0 days/year) (P< 0.001). The mean follow-up interval was 22 (SD = ±7) months.Lessons learnedA knowledge-translation framework can guide multi-level organizational change, facilitate asthma guideline implementation, and improve health outcomes in community primary care practices. Program costs are similar to those of diabetes programs. Program savings offset costs in a ratio of 2.1:1.

PMID: 22893665 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

“Asthma Global Clinical Trials Review, H1, 2012” Now Available at Fast Market … – SBWire (press release)

"Asthma Global Clinical Trials Review, H1, 2012" Now Available at Fast Market
SBWire (press release)
Boston, MA — (SBWIRE) — 07/24/2012 — GlobalData's clinical trial report, "Asthma Global Clinical Trials Review, H1, 2012" provides data on the Asthma clinical trial scenario. This report provides elemental information and data relating to the

and more »

View full post on asthma – Google News

Evaluating and managing pediatric food allergy – Clinical Advisor

Evaluating and managing pediatric food allergy
Clinical Advisor
For example, children with food allergy are four times more likely to have asthma, two times more likely to have atopic dermatitis, and nearly four times more likely to have respiratory allergies compared with children who have no food allergy. The
Food allergies among adolescents more common in Israel than in Britain, study Haaretz

all 2 news articles »

View full post on asthma – Google News